NGNE
Neurogene Inc
28.30$
-9.4%
vs. previous close
Closing price · As of: Sep 25, 2026
Statements
Balance Sheet
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | +173.6% | +36.2% | -28.5% | -29.6% | +89.4% | +43.2% | -51.8% | +7.7% | +103.7% | +50.8% | -14.0% | |
| – | +90.3% | +38.4% | +5.2% | -29.1% | +86.1% | +35.5% | -62.0% | +14.6% | +136.5% | +57.7% | -14.0% | |
| – | +165.2% | -18.3% | +61.1% | +47.8% | +86.0% | +34.6% | -63.4% | +16.3% | +80.7% | -7.8% | -24.0% | |
| – | +90.5% | +38.4% | +4.9% | -28.8% | +86.0% | +34.6% | -63.4% | +16.3% | +140.4% | +58.5% | -13.9% | |
| – | -51.1% | – | – | – | – | – | – | +25.3% | -39.4% | +8.0% | – | |
| – | – | – | – | – | – | – | – | -43.6% | +38.8% | – | – | |
| – | – | – | – | – | – | -38.8% | -63.1% | – | – | – | – | |
| – | -6.7% | +97.4% | +17.8% | -56.8% | +7.9% | +261.8% | +901.7% | -94.5% | +243.6% | -30.6% | -6.5% | |
| – | -7.9% | +98.6% | +15.1% | -57.8% | +2.5% | +66.3% | +37.6% | -38.7% | +245.4% | -34.0% | +8.3% | |
| – | – | – | – | – | – | +14.6% | +158.6% | -61.7% | +310.5% | +4.1% | +2.2% | |
| – | – | – | – | – | +128.5% | -17.5% | +325.5% | -88.9% | +315.4% | -48.5% | +46.2% | |
| – | +199.9% | +33.4% | -31.6% | -26.5% | +95.0% | +35.0% | -148.0% | – | +88.6% | +66.8% | -14.7% | |
| – | – | – | – | – | – | – | – | – | – | – | – | |
| – | +45.8% | +49.5% | +24.1% | +0.3% | +14.9% | +91.7% | +6.2% | -76.7% | +0.0% | +37.0% | +20.5% |
Data as of: September 25, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.